What is TheraVectys?
TheraVectys is a pioneering biotechnology enterprise dedicated to revolutionizing global healthcare through the development of lentiviral vector-based vaccines. The company focuses on addressing high-unmet medical needs, specifically targeting oncology and infectious diseases. By utilizing a sophisticated platform that facilitates both preventative and therapeutic applications, TheraVectys has established a robust portfolio of candidates. Their operational model is characterized by strategic partnerships, including a notable joint-laboratory with the Institut Pasteur, and international collaborations spanning Europe, North America, and China. The company is currently transitioning from pre-clinical proof-of-concept studies to active clinical trials, aiming to validate its technology through phase I/IIa assays for conditions such as hepatitis B, liver cancer, and respiratory viral infections.
How much funding has TheraVectys raised?
TheraVectys has raised a total of $51.4M across 4 funding rounds:
Private Equity
$9.4M
Unspecified
$19.9M
Grant
$2.1M
Unspecified
$20M
Private Equity (2012): $9.4M, investors not publicly disclosed
Unspecified (2013): $19.9M led by FGP Capital
Grant (2015): $2.1M supported by Bpifrance
Unspecified (2021): $20M, investors not publicly disclosed
Key Investors in TheraVectys
Bpifrance
A French public investment bank that provides comprehensive financial support to companies at every stage of development, focusing on innovation, international expansion, and equity financing.
FGP Capital
A Swiss-based investment firm specializing in late-stage healthcare and technology opportunities, with a particular emphasis on financing clinical research and university spin-offs.
Undisclosed Investor
An undisclosed institutional partner participating in the latest funding round to support the advancement of clinical-stage immunotherapy assets.
What's next for TheraVectys?
With the recent influx of capital, TheraVectys is poised to enter a high-growth phase characterized by intensive clinical validation. The strategic roadmap includes the initiation of proprietary Phase I/IIa clinical trials, which are essential for demonstrating the efficacy of their lentiviral technology in human subjects. Furthermore, the company intends to deepen its industrial collaborations to scale manufacturing and regulatory approval processes. As TheraVectys moves toward commercialization, the focus will remain on establishing its platform as a standard in immunotherapy, potentially disrupting traditional vaccine development paradigms and creating significant long-term value for stakeholders in the global life sciences market.
See full TheraVectys company page
